$IBRX

FDA flagged ImmunityBio for unsupported Anktiva cancer cure claims. Company implemented corrective measures while reporting 750% unit volume growth and $38.29M quarterly revenue.

Rosen Law Firm files securities class action against Snowflake alleging executives concealed material information about product efficiency and pricing changes affecting consumption and revenues.

Rosen Law Firm initiates securities lawsuit against $IBRX over alleged false statements regarding Anktiva capabilities. Lead plaintiff deadline: May 26, 2026.

Class action lawsuit filed against Pinterest for allegedly making false statements about advertising revenues and tariff impacts. Stock plunged 16.8% after Q4 results missed expectations.

Kirby McInerney LLP filed securities fraud lawsuit against ImmunityBio over allegedly misleading Anktivas marketing. FDA warning letter triggered 21.2% stock decline.

ImmunityBio faces securities lawsuit after FDA warns of misleading Anktiva efficacy claims. Stock plunges 21%, erasing $2B in market value.

ImmunityBio faces securities fraud lawsuit following FDA warning letter about Anktiva cancer therapy misleading ads. Stock plummeted to $7.42.

ImmunityBio ($IBRX) shares plunged 21% after FDA warning over false Anktiva efficacy claims, erasing $2 billion in market value and triggering securities litigation.

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.

ImmunityBio shares plunge 21% after FDA warning over unsupported cancer treatment claims, erasing $2 billion in market value and triggering securities litigation.

Global cell therapy manufacturing market projected to reach $14B by 2035, with FDA regulatory flexibility accelerating approvals and multiple biotech companies advancing scalable production capabilities.

Rosen Law Firm filed a class action lawsuit against ImmunityBio ($IBRX), alleging founder Patrick Soon-Shiong materially overstated Anktiva's capabilities, impacting investors.

Rosen Law Firm filed a securities class action against Kyndryl Holdings alleging false disclosures on financials and internal controls, with an April 2026 lead plaintiff deadline.

Class action lawsuit filed against ImmunityBio for allegedly making false statements about cancer treatment Anktiva. FDA issued warning letter; stock fell 21% after disclosure.

ImmunityBio stock surged 11.2% after Macau approved its bladder cancer drug Anktiva, marking the company's first Asian regulatory victory and potential gateway for regional expansion.

ImmunityBio stock rises 2.01% after NCCN includes Anktiva bladder cancer therapy in updated clinical guidelines; FDA resubmission underway.

ImmunityBio shares surge 10.6% after completing NK cell manufacturing programs producing five billion cells safely, plus FDA acknowledges ANKTIVA resubmission for bladder cancer.

Lucid Group tops the most-shorted stocks list as of March 11, 2026, highlighting investor skepticism toward struggling EV manufacturers amid broader market volatility.

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.

ImmunityBio launches 85-person European sales team for bladder cancer drug Anktiva across 30 countries, partnering with Accord Healthcare and establishing an Irish subsidiary for distribution.